Journal of Clinical Sleep Medicine最新文献

{"title":"Efficacy of psychological interventions on sleep in children and adolescents with chronic pain: a systematic review with meta-analysis of randomized controlled trials.","authors":"Tanya L Thwaite, Emma A Craige, Niamh Mundell, Daniel L Belavy, Scott D Tagliaferri, Kate Vincent, Sally A Ferguson, Madeline Sprajcer, Patrick J Owen, Grace E Vincent","doi":"10.5664/jcsm.11678","DOIUrl":"https://doi.org/10.5664/jcsm.11678","url":null,"abstract":"<p><strong>Study objectives: </strong>Chronic pain and comorbid sleep difficulties impacts many children and adolescents. This study aimed to evaluate the efficacy of psychological interventions on sleep in children and adolescents with chronic pain.</p><p><strong>Methods: </strong>Five databases (PubMed, CINAHL, APA PsychInfo, Embase, CENTRAL) were searched from inception to 17 April 2023 for randomized controlled trials examining the effects of psychological interventions on sleep in participants aged ≤19 years with pain persisting for ≥12 weeks. Six studies (participants, <i>n</i> = 686; 78.43% female) were included. Cochrane risk-of-bias 2 and GRADE were employed.</p><p><strong>Results: </strong>Pairwise random-effects restricted maximum likelihood meta-analysis demonstrated no effect of psychological interventions on sleep (<i>g</i> [95%CI]: -0.04 [-0.19, 0.11], <i>p</i> = .613, GRADE: high), pain intensity (0.05 [-0.17, 0.27], <i>p =</i> .563, GRADE: high), depressive symptomatology (0.17 [-0.27, 0.62], <i>p =</i> .304, GRADE: moderate) or anxious symptomatology (<i>g</i> [95%CI]: 0.13 [-0.32, 0.57], <i>p =</i> .351, GRADE: moderate). Subjective outcomes may limit clinical utility, and risk of bias (some concern for all studies) decreased confidence in effect estimates.</p><p><strong>Conclusions: </strong>Development and evaluation of psychological interventions specifically tailored to address comorbidities of sleep difficulties in child and adolescent chronic pain populations is warranted. <b>Systematic Review Registration:</b> Registry: PROSPERO; Identifier: CRD42023454620.</p>","PeriodicalId":50233,"journal":{"name":"Journal of Clinical Sleep Medicine","volume":" ","pages":""},"PeriodicalIF":3.5,"publicationDate":"2025-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143702096","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Adherence to unilateral hypoglossal nerve stimulation and changes in Epworth Sleepiness Scale scores.","authors":"Emily A Commesso, Cyrus Haghighian, Eric J Kezirian","doi":"10.5664/jcsm.11620","DOIUrl":"https://doi.org/10.5664/jcsm.11620","url":null,"abstract":"<p><strong>Study objectives: </strong>Effective treatment of obstructive sleep apnea depends on efficacy and adherence. The objective of this analysis was to examine the association between adherence to unilateral hypoglossal nerve stimulation (HGNS, Inspire Upper Airway Stimulation) and changes in daytime sleepiness.</p><p><strong>Methods: </strong>Participants were adults treated with unilateral HGNS enrolled in the ADHERE Registry. All participants included in the analysis completed a final visit 1-2 years following implantation. Outcomes were the change in Epworth Sleepiness Scale (ESS) score and normalization of a baseline abnormal ESS score (baseline ESS>10 and final ESS≤10). Statistical analyses examined the association between objective therapy adherence and ESS outcomes, with multiple regression including adjustment for age, sex, race, ethnicity, body mass index (BMI), and apnea-hypopnea index (AHI)-defined responder status.</p><p><strong>Results: </strong>The analysis included 1147 participants who were primarily middle-aged (59.7 ± 10.5 years), overweight (BMI 29.1 ± 3.7), Caucasian (95.8%), male (76.8%), and with severe OSA (AHI 35.12 ± 14.81). ESS scores decreased from 11.3 ± 5.5 at baseline to 6.9 ± 4.6 at final visit. Of those with baseline ESS>10, 68% (441/644) achieved normalized ESS scores at final visit. Multiple regression analyses showed that each additional hour/night of therapy use was associated with decrease in ESS score (0.17, p=0.045) and increased odds of normalized ESS (OR 1.13; 95% CI: 1.03-1.25). AHI response was also associated with decrease in ESS score (1.29, p<0.001) and increased odds of a normalized ESS (OR 2.29; 95% CI: 1.55-3.4).</p><p><strong>Conclusions: </strong>Adherence to HGNS is associated with improvement in daytime sleepiness symptoms and increased odds of achieving normalization of daytime sleepiness.</p>","PeriodicalId":50233,"journal":{"name":"Journal of Clinical Sleep Medicine","volume":" ","pages":""},"PeriodicalIF":3.5,"publicationDate":"2025-03-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143694035","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The association between sleep fragmentation and incident atrial fibrillation: a prospective cohort study in a community population.","authors":"Lixia Wang, Xinjie Hui, Rong Huang, Yi Xiao","doi":"10.5664/jcsm.11614","DOIUrl":"https://doi.org/10.5664/jcsm.11614","url":null,"abstract":"<p><strong>Study objectives: </strong>Sleep fragmentation (SF) has been recognized as a risk factor for cardiovascular disease. This study aims to investigate the impact of SF on atrial fibrillation (AF).</p><p><strong>Methods: </strong>A total of 2377 participants without pre-existing AF from the Sleep Heart Health Study were enrolled in this study. Wake after sleep onset (WASO), sleep fragmentation index (SFI), arousal index (ArI), and sleep efficiency (SE) were used to describe SF objectively. Multivariate logistic regression and restricted cubic spline analysis were conducted to investigate the association between SF and AF.</p><p><strong>Results: </strong>During a mean follow-up of 5.3 years, we observed 221 (9.30%) participants developed AF. Participants with incident AF had significantly worse WASO, ArI, and SE compared with those without incident AF. Multivariate logistic regression revealed that WASO was associated with incident AF in both overall sample and participants without obstructive sleep apnea (OSA), with odds ratios (ORs) of 1.61 (95%CI: 1.04, 2.49; <i>P</i>=0.033) and 5.89 (95%CI: 2.18, 19.16; <i>P</i>=0.001) for the fourth quartile of WASO, respectively. The first quartile of SE (OR, 3.51; 95%CI: 1.28, 10.49; <i>P</i> = 0.019) and the fourth quartile of ArI (OR, 3.16; 95%CI: 1.23, 9.01; <i>P</i> = 0.021) were associated with incident AF in participants without OSA.</p><p><strong>Conclusions: </strong>This study demonstrated that worsening SF, as assessed by WASO, SE, and ArI, was associated with an increased odds of incident AF in participants without OSA. Thus, improving SF may contribute to decreasing the odds of incident AF.</p>","PeriodicalId":50233,"journal":{"name":"Journal of Clinical Sleep Medicine","volume":" ","pages":""},"PeriodicalIF":3.5,"publicationDate":"2025-03-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143694027","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Accuracy and acceptability of home sleep apnea testing with electroencephalography compared to in-lab polysomnography for the diagnosis of obstructive sleep apnea in children.","authors":"Darko Stefanovski, Mahalakshmi Somayaji, Michelle Ward, Jennifer Falvo, Mary Anne Cornaglia, Ignacio E Tapia, Yaelis Roman, Melissa Xanthopoulos, Christopher M Cielo","doi":"10.5664/jcsm.11654","DOIUrl":"https://doi.org/10.5664/jcsm.11654","url":null,"abstract":"<p><strong>Study objectives: </strong>In-laboratory polysomnography is recommended for the evaluation of obstructive sleep apnea (OSA) in children, but availability is limited. We hypothesized that home sleep apnea testing including electroencephalogram (HSAT) could accurately detect OSA in children and be an alternative to polysomnography.</p><p><strong>Methods: </strong>Children clinically referred for polysomnography underwent testing with the HSAT device twice: once in their home as well as concurrently with in-lab polysomnography (portable lab testing [PLT]). HSAT and PLT were compared to reference polysomnography for OSA diagnosis using an obstructive apnea-hypopnea index (OAHI) greater than 2 events/hour. OAHI cutoffs of 1 and 5 events/hour were explored. The diagnostic accuracy was further analyzed using the area under the receiver operating characteristics curve (AUC ROC).</p><p><strong>Results: </strong>All 15 participants, median (range) age 8.1 (2.9-17.1) years completed in-lab testing and HSAT. OSA was identified by polysomnography in 7 (47%) participants. HSAT correctly identified OSA status from polysomnography in 14 (93%). OAHI was similar between polysomnography [1.7 (0, 26) events/hour] and PLT [1.6 (0.3, 24.4)] and HSAT [1.8 (0.3, 23)], p=0.98. HSAT OAHI showed strong correlation with polysomnography OAHI (Spearman's r = 0.8, p=0.0001). AUC ROC referenced with polysomnography were excellent using OAHI threshold values of 1,2, and 5 compared with PLT (AUC ROC=0.96, 0.96, 1) and HSAT (AUC ROC= 0.79, 0.95, 0.98 respectively).</p><p><strong>Conclusions: </strong>HSAT with EEG was accurate compared to polysomnography for the diagnosis of pediatric OSA. Electroencephalography may improve the diagnostic accuracy of HSAT in children, particularly for mild OSA and younger children.</p>","PeriodicalId":50233,"journal":{"name":"Journal of Clinical Sleep Medicine","volume":" ","pages":""},"PeriodicalIF":3.5,"publicationDate":"2025-03-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143694021","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Oral appliance therapy is highly efficacious at reducing sleep apnea-specific hypoxic burden, a metric predictive of cardiovascular morbidity and mortality.","authors":"Erin V Mosca, Joshua Grosse, John E Remmers","doi":"10.5664/jcsm.11622","DOIUrl":"https://doi.org/10.5664/jcsm.11622","url":null,"abstract":"<p><strong>Study objectives: </strong>A surrogate metric of obstructive sleep apnea (OSA), sleep apnea-specific hypoxic burden (SASHB), predicts adverse health outcomes associated with the disease and may be useful in assessing therapeutic success. The purpose of this study was to compare outcome of mandibular protruding oral appliance therapy (OAT) using apnea-hypopnea index (AHI) and SASHB in a population with a spectrum of OSA severity.</p><p><strong>Methods: </strong>Individuals with mild, moderate, and severe OSA (n = 152) were treated with mandibular protruding oral appliance therapy (OAT) in a prospective observational study. Two-night home sleep apnea tests were used to determine baseline and outcome values of AHI and SASHB.</p><p><strong>Results: </strong>Mean baseline SASHB differed by OSA severity strata, with 0%, 18%, and 95% the percent of study participants with mild, moderate and severe OSA, respectively, having values greater than 60%min/h. At outcome, these values were reduced to 0%, 0%, and 15%, respectively. For the entire population, therapeutic efficacy was 75% using AHI < 10 events/h as a response criterion and 95% using SASHB < 60%min/h as the criterion.</p><p><strong>Conclusions: </strong>Using a risk-predictive outcome surrogate to assess the efficacy of OAT yields a substantially higher estimate of therapeutic efficacy of OAT, particularly in patients with severe OSA.</p><p><strong>Clinical trial registration: </strong>Registry: ClinicalTrials.gov; Name: Feasibility and Predictive Accuracy of an In-Home Computer Controlled Mandibular Positioner in Identifying Favorable Candidates for Oral Appliance Therapy; Identifier: NCT03011762; Registry: ClinicalTrials.gov; Name: Predictive Accuracy of MATRx Plus in Identifying Favorable Candidates for Oral Appliance Therapy; Identifier: NCT03217383; Registry: ClinicalTrials.gov; Name: Validation of a Simplified MATRx Plus; Identifier: NCT03812692.</p>","PeriodicalId":50233,"journal":{"name":"Journal of Clinical Sleep Medicine","volume":" ","pages":""},"PeriodicalIF":3.5,"publicationDate":"2025-03-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143694026","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluation of sleep-wake disorders with the Kiddie Schedule for Affective Disorders and Schizophrenia for Children and Adolescents: Present and Lifetime Version 5.1.","authors":"Francisco R de la Peña, Rosa Elena Ulloa, Marcos F Rosetti, Ricardo Díaz Sánchez, Alejandro Irvin Soto-Briseño, Liz Sosa-Mora, Miriam Feria-Aranda, Pablo Adolfo Mayer-Villa, José Carlos Medina-Rodríguez","doi":"10.5664/jcsm.11668","DOIUrl":"https://doi.org/10.5664/jcsm.11668","url":null,"abstract":"<p><strong>Study objectives: </strong>Sleep-wake disorders (SWD) include dyssomnias and parasomnias, which negatively impact cognitive, emotional, and physical functioning, contributing to significant disability. The aims were to develop and evaluate the convergent validity (CV), divergent validity (DV), and inter-rater reliability (IR) of the Kiddie Schedule for Affective Disorders and Schizophrenia Present and Lifetime Version 5.1 (K-SADS-PL-5.1), which includes SWD.</p><p><strong>Methods: </strong>We calculated categorical, sub-dimensional, and dimensional SWD. We evaluated 103 children and adolescents, n=43 females (41.75%), with a mean age of 13.35 (SD=2.97).</p><p><strong>Results: </strong>For categorical SWD, the highest prevalence was observed for insomnia disorder, n=64 (62.1%), while the lowest was for non-REM sleep arousal disorders, n=15 (14.6%). For categorical diagnoses, CV showed correlations from (r=0.27 to r=0.58) and for DV from (r=-0.00 to r=-0.14). For the sub-dimension of dyssomnias, the CV reported (r=0.38) with the Sleep Disorder Rating Scale (SDRS), and the DV value with the Strength and Difficulties Questionnaire (SDQ) was (r=-0.08) and for the MOJAVE scale was (r=0.00). For the sub-dimension of parasomnias, the CV value with the SDRS was (r=0.36), and the DV values were with the SDQ (r=0.11) and with the MOJAVE (r=0.007). For the dimension of SWD, the CV value with the SDRS was (r=0.41), while the DV values were for SDQ (r=0.02) and the MOJAVE (r=0.01).</p><p><strong>Conclusions: </strong>IR demonstrated excellent correlation between evaluators (κ=0.85 to 0.90). The K-SADS-PL-5.1 is a valid and reliable tool for diagnosing SWD in children and adolescents.</p>","PeriodicalId":50233,"journal":{"name":"Journal of Clinical Sleep Medicine","volume":" ","pages":""},"PeriodicalIF":3.5,"publicationDate":"2025-03-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143693981","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Images: Atypical resolution of sleep-related hypoventilation in congenital central hypoventilation syndrome.","authors":"Michelle Yoo, Amit Shah, Haitham Shahrour, Hong Li, Ajay S Kasi","doi":"10.5664/jcsm.11644","DOIUrl":"https://doi.org/10.5664/jcsm.11644","url":null,"abstract":"<p><p>Paired-like homeobox 2B (<i>PHOX2B</i>) gene variants cause congenital central hypoventilation syndrome (CCHS) characterized by abnormal ventilatory control necessitating lifelong assisted ventilation (AV). We report a 3-year-old girl who presented with apnea, hypoxemia, hypoventilation requiring AV, and Hirschsprung's disease during infancy followed by resolution of hypoventilation. At 3 weeks, polysomnography showed obstructive and central sleep apnea, oxygen desaturations, and hypoventilation. A novel, heterozygous, paternal-inherited 2.77 Mb deletion in chromosome 4p14-p13 resulted in deletion of the entire <i>PHOX2B</i> gene, confirming the diagnosis of CCHS. <i>PHOX2B</i> whole-gene deletions are categorized as nonpolyalanine repeat mutations. AV via tracheostomy was utilized during sleep. At 2.8 years, diagnostic polysomnography was performed due to suboptimal adherence to AV that demonstrated central sleep apnea without hypoxemia or hypoventilation. There were no signs of chronic hypoventilation such as polycythemia, elevated serum bicarbonate, or pulmonary hypertension. CCHS is characterized by lifelong hypoventilation requiring AV. Despite a classic presentation of CCHS requiring early tracheostomy, polysomnography at 3 years of age indicated an absence of hypoventilation that represents a unique and atypical presentation in CCHS.</p>","PeriodicalId":50233,"journal":{"name":"Journal of Clinical Sleep Medicine","volume":" ","pages":""},"PeriodicalIF":3.5,"publicationDate":"2025-03-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143671717","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The effects of cognitive behavioral therapy for insomnia in patients with cardiovascular disease: a systematic review and meta-analysis.","authors":"Silje Glenna Andersen, Henrik Sæterhagen, André Pekkola Pacheco, Are Hugo Pripp, Harald Hrubos-Strøm, Costas Papageorgiou, John Munkhaugen, Toril Dammen","doi":"10.5664/jcsm.11656","DOIUrl":"https://doi.org/10.5664/jcsm.11656","url":null,"abstract":"<p><strong>Study objectives: </strong>Insomnia affects up to 50% of patients with cardiovascular diseases (CVD) and is associated with poor clinical outcomes. Cognitive behavioral therapy for insomnia (CBT-I) is the recommended first-line treatment for insomnia, but little is known on the effects of CBT-I in patients with established CVD. We aimed to investigate the effects of CBT-I on insomnia symptom severity, sleep parameters, and daytime symptoms in patients with CVD and comorbid insomnia.</p><p><strong>Methods: </strong>Medline, Embase, PsycINFO and ClinicalTrials.gov were searched for randomized controlled and open trials up to December 2023. Study selection, data extraction, and risk of bias assessment (Cochrane's risk of bias 2 tool) were independently conducted by co-authors. Data were meta-analyzed using random-effects models.</p><p><strong>Results: </strong>In all, 1275 records with five studies fulfilled the inclusion criteria (n=352 patients). Compared with active control groups, CBT-I significantly reduced insomnia severity post-treatment (standardized mean difference [SMD] = -0.90, 95%CI: -1.43, -0.37, p < .001), sleep onset latency (SOL), anxiety, and fatigue. Moreover, CBT-I significantly improved sleep quality (SMD = -0.77, 95%CI: -1.10, -0.45, p < .001) and sleep efficiency (SMD = 0.68, 95%CI: 0.12-1.25, p < .001). We regarded three RCTs as having low risk of bias, and had some concerns with another.</p><p><strong>Conclusions: </strong>Evidence from our analyses indicated that CBT-I seems to be effective for alleviating insomnia symptoms among CVD patients, largely in line with the results of previous meta-analyses in patients with insomnia. The limited sample size encourages more robust evidence from high-quality, large-scale trials with long-term follow-up.</p><p><strong>Systematic review registration: </strong>Registry: PROSPERO; Identifier: CRD4202448873; Title: Effects of cognitive behavioral therapy for insomnia in patients with coronary heart disease: A systematic review; URL: https://www.crd.york.ac.uk/PROSPERO/view/CRD42024488739.</p>","PeriodicalId":50233,"journal":{"name":"Journal of Clinical Sleep Medicine","volume":" ","pages":""},"PeriodicalIF":3.5,"publicationDate":"2025-03-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143671678","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Personalized endpoints in Prader-Willi syndrome: a case study with goal attainment scaling.","authors":"Amee Revana, Gunes Sevinc, Michelle George, Taylor Dunn, Kari Pope, Justin Stanley, Kenneth Rockwood","doi":"10.5664/jcsm.11664","DOIUrl":"https://doi.org/10.5664/jcsm.11664","url":null,"abstract":"<p><p>This case report examines the implementation of Goal Attainment Scaling (GAS) for a 9-year-old girl with Prader-Willi Syndrome (PWS) and narcolepsy-like features who began treatment with Pitolisant, a medication designed to alleviate excessive daytime sleepiness. The individualized GAS framework enabled the patient and her caregivers to establish specific treatment goals across cognitive, motor, and physiological domains. Although validated outcome measures for this population are limited, GAS effectively captured crucial aspects of the patient's experience, revealing overall improvements in most symptoms during a six-month follow-up. This method provided an unbiased assessment of treatment effectiveness, underscoring the importance of integrating patient-centered measures in the management of rare diseases like PWS. The findings suggest that GAS can yield valuable insights into patient priorities and treatment outcomes, highlighting the need for further research into its application in clinical settings for PWS and similar conditions.</p>","PeriodicalId":50233,"journal":{"name":"Journal of Clinical Sleep Medicine","volume":" ","pages":""},"PeriodicalIF":3.5,"publicationDate":"2025-03-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143671723","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluating the potential of metabolic drugs in obstructive sleep apnea and obesity: a narrative review.","authors":"Beyza Sevencan, Nele Steenackers, Amar Daniël Emanuel van Laar, Sofía Pazmiño Lucio, Bertien Buyse, Alexandros Kalkanis, Dries Testelmans, Bart Van der Schueren","doi":"10.5664/jcsm.11682","DOIUrl":"https://doi.org/10.5664/jcsm.11682","url":null,"abstract":"<p><strong>Study objectives: </strong>To assess the effectiveness of sodium-glucose cotransporter-2 (SGLT2) inhibitors, glucagon-like peptipte-1 (GLP-1) receptor agonists and dual gastric inhibitory polypeptide/glucagon-like peptipte-1 (GIP/GLP-1) receptor agonists in the treatment of obstructive sleep apnea.</p><p><strong>Methods: </strong>A comprehensive literature search was performed across multiple medical databases, including Embase, Medline, and Cochrane to look for English articles on interventions with SGLT2 inhibitors, GLP-1 and dual GIP/GLP-1 receptor agonists in people living with sleep apnea and overweight or obesity.</p><p><strong>Results: </strong>Emerging evidence indicates that SGLT2 inhibitors, GLP-1 and dual GIP/GLP-1 receptor agonists are beneficial for treating obesity in combination with sleep apnea. While these medications have shown promise in weight reduction, with GLP-1 receptor agonists slightly outperforming SGLT2 inhibitors, their effect on sleep apnea extends beyond mere weight loss. Preliminary studies suggest a beneficial role in obstructive sleep apnea management with reductions in the Apnea-Hypopnea Index (AHI) and potential improvements in other sleep-related outcomes.</p><p><strong>Conclusions: </strong>There is a need for more therapeutic options to treat sleep apnea as adherence with current treatment options remains a struggle for many patients. According to preliminary research, SGLT2 inhibitors, GLP-1 and dual GIP/GLP-1 receptor agonists are promising candidates as they do show beneficial effects on AHI and weight. Nevertheless, large-scale clinical trials are needed to assess their clinical potential and risk balance in more detail.</p>","PeriodicalId":50233,"journal":{"name":"Journal of Clinical Sleep Medicine","volume":" ","pages":""},"PeriodicalIF":3.5,"publicationDate":"2025-03-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143671715","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}